International Journal of Clinical Pharmacy

, Volume 40, Issue 5, pp 1030–1036 | Cite as

Preliminary experience of tigecycline treatment for infection in children with hematologic malignancies

  • Shupeng Lin
  • Chenmei Zhang
  • Sheng YeEmail author
Research Article


Background Severe infection is life-threatening in children with hematologic malignancies and its treatment is challenging because of an increasing number of multidrug-resistant pathogens. Tigecycline has an expanded antibacterial activity spectrum; some successful cases of tigecycline treatment have been reported in the literature. Objective To examine the efficacy and safety of tigecycline in children. Setting Department of hematologic malignancies in a tertiary hospital. Method A retrospective chart review from May 1, 2012 to May 1, 2017. The patients were identified by the hospital information system and a custom-made Microsoft Excel 2007 database of patients was created to record demographic and medical data. Main outcome measure Efficacy and safety of tigecycline use in severe infection children with hematologic malignancies. Results Thirty-seven patients were enrolled and the predominant diagnosis was acute lymphoblastic leukemia. The median duration of tigecycline therapy was 9 days. Most prescriptions were empirical. Eighteen patients received a maintenance dose of 2 mg/kg q12 h, without a loading dose. Sulperazone was the most frequently prescribed concomitant drug. At the end of tigecycline therapy, improvement was observed in 48.7% of cases. After treatment, interleukin-10 levels notably decreased. The only reported adverse event was a case of tooth discoloration. Conclusion Tigecycline can be used as salvage therapy in children with hematologic malignancy and seems tolerable. Prospective controlled studies are required to definitively evaluate the efficacy and safety of tigecycline in children.


Hematologic malignancies Neutropenia Pediatrics Severe infections Tigecycline 



The authors wish to thank Chanchan Hu and Lingfang Liang for their help with data collection. We also thank Professor Yongmin Tang in the Hematology department of our hospital for his advice.


This study was supported in part by grants from the Zhejiang Medical and Health Science and Technology Plan Project (2007B119), the Zhejiang Medical and Health Science and Technology Plan Project (2012KYB119), and the Natural Science Foundation of Zhejiang Province (LY12H19006).

Conflicts of interest

There are no conflicts of interest to declare.


  1. 1.
    Fiser RT, West NK, Bush AJ, Sillos EM, Schmidt JE, Tamburro RF. Outcome of severe sepsis in pediatric oncology patients. Pediatr Crit Care Med. 2005;6(5):531–6.CrossRefGoogle Scholar
  2. 2.
    Averbuch D, Avaky C, Harit M, Stepensky P, Fried I, Ben-Ami T, et al. Non-fermentative gram-negative rods bacteremia in children with cancer: a 14-year single-center experience. Infection. 2017;45(3):327–34. Scholar
  3. 3.
    Purdy J, Jouve S, Yan JL, Balter I, Dartois N, Cooper CA, et al. Pharmacokinetics and safety profile of tigecycline in children aged 8–11 years with selected serious infections: a multicenter, open-label, ascending-dose study. Clin Ther. 2012;34(2):496–507 e1. Scholar
  4. 4.
    Wyeth Pharmaceuticals Inc. asoPI. TYGACIL- tigecycline injection, powder, lyophilized, for solution. 2005. Accessed 02 Apr 2018.
  5. 5.
    Dinleyici EC, Yargic ZA, Bor O, Kiremitci A, Durmaz G. Tigecycline treatment of multi-drug-resistant Corynebacterium jeikeium infection in a child with relapsing and refractory acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010;55(2):349–51. Scholar
  6. 6.
    Foresti S, Di Bella S, Rovelli A, Sala A, Verna M, Bisi L, et al. Tigecycline lock therapy for catheter-related bloodstream infection caused by KPC-producing Klebsiella pneumoniae in two pediatric hematological patients. Antimicrob Agents Chemother. 2015;59(12):7919–20. Scholar
  7. 7.
    Maximova N, Zanon D, Verzegnassi F, Granzotto M. Neutrophils engraftment delay during tigecycline treatment in 2 bone marrow-transplanted patients. J Pediatr Hematol Oncol. 2013;35(1):e33–7. Scholar
  8. 8.
    Tugcu D, Turel O, Aydogan G, Akcay A, Salcioglu Z, Akici F, et al. Successful treatment of multiresistant Achromobacter xylosoxidans bacteremia in a child with acute myeloid leukemia. Ann Saudi Med. 2015;35(2):168–9. Scholar
  9. 9.
    Takeda T, Hatae Y, Nakadate H, Fujita K, Suzuki Y, Wagatsuma Y, et al. A multi-institutional study on the efficacy and toxicity of imipenem/cilastatin sodium in severe infections complicating hematological diseases and cancers in children. Study group of infectious diseases in pediatric hematology/oncology in Hokkaido. Jpn J Antibiot. 1993;46(5):388–96.PubMedGoogle Scholar
  10. 10.
    Zengin E, Sarper N, Kilic SC. Piperacillin/tazobactam monotherapy versus piperacillin/tazobactam plus amikacin as initial empirical therapy for febrile neutropenia in children with acute leukemia. Pediatr Hematol Oncol. 2011;28(4):311–20. Scholar
  11. 11.
    Schwab KS, Hahn-Ast C, Heinz WJ, Germing U, Egerer G, Glasmacher A, et al. Tigecycline in febrile neutropenic patients with haematological malignancies: a retrospective case documentation in four university hospitals. Infection. 2014;42(1):97–104. Scholar
  12. 12.
    Yagnik RM, Benzeroual KE. Tigecycline prevents LPS-induced release of pro-inflammatory and apoptotic mediators in neuronal cells. Toxicol Vitro. 2013;27(2):686–93. Scholar
  13. 13.
    Salvatore CM, Techasaensiri C, Tagliabue C, Katz K, Leos N, Gomez AM, et al. Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia. Antimicrob Agents Chemother. 2009;53(4):1546–51. Scholar
  14. 14.
    von Seth M, Sjolin J, Larsson A, Eriksson M, Hillered L, Lipcsey M. Effects of tigecycline and doxycycline on inflammation and hemodynamics in porcine endotoxemia: a prospective, randomized, and placebo-controlled trial. Shock. 2015;43(6):604–11. Scholar
  15. 15.
    Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother. 2006;58(6):1221–9. Scholar
  16. 16.
    Iosifidis E, Violaki A, Michalopoulou E, Volakli E, Diamanti E, Koliouskas D, et al. Use of tigecycline in pediatric patients with infections predominantly due to extensively drug-resistant gram-negative bacteria. J Pediatr Infect Dis Soc. 2017;6(2):123–8. Scholar
  17. 17.
    Zhu ZY, Yang JF, Ni YH, Ye WF, Wang J, Wu ML. Retrospective analysis of tigecycline shows that it may be an option for children with severe infections. Acta Paediatr. 2016;105(10):e480–4. Scholar
  18. 18.
    Dizbay M, Altuncekic A, Sezer BE, Ozdemir K, Arman D. Colistin and tigecycline susceptibility among multidrug-resistant Acinetobacter baumannii isolated from ventilator-associated pneumonia. Int J Antimicrob Agents. 2008;32(1):29–32. Scholar
  19. 19.
    Prot-Labarthe S, Youdaren R, Benkerrou M, Basmaci R, Lorrot M. Pediatric acute pancreatitis related to tigecycline. Pediatr Infect Dis J. 2010;29(9):890–1. Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Division of Hematology-OncologyChildren’s Hospital Zhejiang University School of MedicineHangzhouChina
  2. 2.Department of Pediatric Intensive Care UnitChildren’s Hospital Zhejiang University School of MedicineHangzhouChina

Personalised recommendations